(2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol is a **complex organic molecule** with a specific chemical structure. It is not a well-known compound, and there is limited information publicly available about its specific properties, uses, or research significance.
Here's why it's hard to find information and why it might be of research interest:
* **It's a custom synthesized compound:** This molecule likely doesn't have a common name or widely available commercial source. It was probably synthesized for a specific research project.
* **Limited published research:** Since it's not a standard chemical reagent, it's unlikely to have extensive published research dedicated to its properties and applications.
* **Potential for pharmaceutical interest:** The structure contains features that could be relevant for medicinal chemistry.
* **Quinoline ring:** Quinoline is a common heterocyclic ring found in many pharmaceuticals, often associated with antimalarial, antibacterial, and anti-inflammatory properties.
* **Methoxyphenyl group:** This group can influence a molecule's biological activity.
* **Piperidine ring:** Piperidine is a cyclic amine found in numerous medications, often contributing to drug activity.
**Here's how to potentially find more information:**
1. **Search scientific databases:** Try searching in specialized chemical databases like SciFinder or Reaxys using the compound's full chemical name.
2. **Check academic journals:** If the compound was synthesized for research purposes, there might be a relevant publication describing its synthesis and properties.
3. **Contact researchers:** If you know of any research groups working on related compounds, reach out to them directly. They might have insights into the molecule's importance.
**Remember:** Without specific research data, it's difficult to determine the exact significance of this compound. Its importance is likely tied to a specific research project and its potential applications are yet to be fully explored.
(2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol: reverses multidrug resistance; NSC 23925b is an isomer. structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 409823 |
CHEMBL ID | 2010123 |
SCHEMBL ID | 559853 |
MeSH ID | M0542374 |
Synonym |
---|
NCI60_001918 |
nsc-23925 |
(2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol |
[2-(4-methoxyphenyl)quinolin-4-yl]-piperidin-2-ylmethanol |
SCHEMBL559853 |
CHEMBL2010123 |
2-(4-methoxyphenyl)-4-quinolinyl(2-piperidinyl)methanol |
NCGC00390402-02 |
PKDJQOGOVQLPPG-UHFFFAOYSA-N |
(2-(4-methoxyphenyl)quinolin-4-yl)(piperidin-2-yl)methanol |
NCGC00390402-04 |
Excerpt | Reference | Relevance |
---|---|---|
" Plasma pharmacokinetic studies of single-dose NSC23925b alone or in combination with paclitaxel or doxorubicin were conducted in male BALB/c mice and Sprague-Dawley rats." | ( Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats. Choy, E; Duan, Z; Gao, Y; Hornicek, FJ; Mankin, HJ; Shen, JK; Zhang, Z, 2016) | 0.43 |
Excerpt | Reference | Relevance |
---|---|---|
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
PPM1D protein | Homo sapiens (human) | Potency | 29.4107 | 0.0052 | 9.4661 | 32.9993 | AID1347411 |
cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 37.9083 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
G | Vesicular stomatitis virus | Potency | 10.6840 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
cytochrome P450 2D6 | Homo sapiens (human) | Potency | 30.1116 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
Interferon beta | Homo sapiens (human) | Potency | 24.7290 | 0.0033 | 9.1582 | 39.8107 | AID1347411; AID1645842 |
HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 10.6840 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 10.6840 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 10.6840 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (9.09) | 29.6817 |
2010's | 7 (63.64) | 24.3611 |
2020's | 3 (27.27) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.21) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (9.09%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (90.91%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |